文献速递癫痫

美国药物难治性颞叶癫痫手术的成本效益

Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US.
PubMed 文献 · Neurology · 2020-07-08

该研究采用半马尔可夫模型评估美国药物难治性颞叶癫痫(DR-TLE)手术及手术评估相对于药物治疗的成本效益。结果显示,在适合手术的患者中,手术相比药物治疗具有成本节省(328,000美元 vs 423,000美元)且更有效(16.6 vs 13.6 QALY),从社会视角看3年内即具成本效益;即使手术候选概率仅5%,手术评估仍具成本效益。

要点

  • 适合手术的DR-TLE患者,手术相比药物治疗成本更低且QALY更高。
  • 从社会视角,手术3年内即具成本效益,89%模拟支持手术优于药物。
  • 即使手术候选概率仅5%,对DR-TLE患者进行手术评估仍具成本效益。

核心结论

  • 对于适合手术的DR-TLE患者,手术相比药物治疗具有成本效益。
  • 对于一般DR-TLE患者,转诊进行手术评估(及可能的手术)具有成本效益。
  • 基于成本效益理由,DR-TLE患者应毫不犹豫地转诊进行手术评估。

研究设计与样本

  • 采用半马尔可夫模型评估手术和手术评估在终身时间范围内的成本效益。
  • 使用二阶蒙特卡洛模拟进行概率敏感性分析以估计模型输出的变异。
  • 采用医疗保健和社会视角,包括直接医疗成本(如手术、抗癫痫药物)和间接成本(如患者和护理人员的收入损失)。

主要发现

  • 在适合手术的患者中,手术相比药物治疗成本节省(328,000美元 vs 423,000美元)且更有效(16.6 vs 13.6 QALY)。
  • 即使被判定为手术候选人的概率仅为5%,手术评估在DR-TLE患者中仍具成本效益。
  • 从社会视角,手术在3年内变得具有成本效益,89%的模拟在终身时间范围内支持手术。

关键数值与推荐

  • 增量成本效益比与社会支付意愿(约100,000美元/QALY)比较以确定成本效益。
  • 手术相比药物治疗:成本328,000美元 vs 423,000美元,QALY 16.6 vs 13.6。
  • 手术评估在手术候选概率低至5%时仍具成本效益。

临床怎么用

  • DR-TLE患者应转诊进行手术评估,无需因成本效益顾虑而犹豫。
  • 适合手术的患者可从手术中获得成本节省和健康收益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Surgery is an effective but costly treatment for many patients with drug-resistant temporal lobe epilepsy (DR-TLE). We aim to evaluate whether, in the United States, surgery is cost-effective compared to medical management for patients deemed surgical candidates and whether surgical evaluation is cost-effective for patients with DR-TLE in general. METHODS: We use a semi-Markov model to assess the cost-effectiveness of surgery and surgical evaluation over a lifetime horizon. We use second-order Monte Carlo simulations to conduct probabilistic sensitivity analyses to estimate variation in model output. We adopt both health care and societal perspectives, including direct health care costs (e.g., surgery, antiepileptic drugs) and indirect costs (e.g., lost earnings by patients and care providers.) We compare the incremental cost-effectiveness ratio to societal willingness to pay (∼$100,000 per quality-adjusted life-year [QALY]) to determine whether surgery is cost-effective. RESULTS: Epilepsy surgery is cost-effective compared to medical management in surgically eligible patients by virtue of being cost-saving ($328,000 vs $423,000) and more effective (16.6 vs 13.6 QALY) than medical management in the long run. Surgical evaluation is cost-effective in patients with DR-TLE even if the probability of being deemed a surgical candidate is only 5%. From a societal perspective, surgery becomes cost-effective within 3 years, and 89% of simulations favor surgery over the lifetime horizon. CONCLUSION: For surgically eligible patients with DR-TLE, surgery is cost-effective. For patients with DR-TLE in general, referral for surgical evaluation (and possible subsequent surgery) is cost-effective. Patients with DR-TLE should be referred for surgical evaluation without hesitation on cost-effectiveness grounds.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sheikh SR, Kattan MW, Steinmetz M, et al. Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US. Neurology. 2020. PMID: 32641528. doi:10.1212/WNL.0000000000010185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。